Loteprednol Etabonate Ophthalmic Ointment 0.5% is a sterile, topical corticosteroid for ophthalmic use. Corticosteroids inhibit the inflammatory response to a variety of inciting agents and probably delay or slow healing. They inhibit the edema, fibrin deposition, capillary dilation, leukocyte migration, capillary proliferation, fibroblast proliferation, deposition of collagen, and scar formation associated with inflammation.  

Corticosteroids are thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of their common precursor arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2. Corticosteroids are capable of producing a rise in intraocular pressure (IOP). The mechanism by which ophthalmic corticosteroids increase intraocular pressure is not known. Indication & Usage: EDNOL Ophthalmic Ointment is a corticosteroid indicated for the treatment of post-operative inflammation and pain following ocular surgery.

Apply a small amount (approximately ½ inch ribbon) into the conjunctival sac(s) four times daily beginning 24 hours after surgery and continuing throughout the first 2 weeks of the post-operative period.

Warnings & Precautions: Intraocular pressure (IOP) increase- Prolonged use of corticosteroids may result in glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision. If this product is used for 10 days or longer, IOP should be monitored even though it may be difficult in children and uncooperative patients. Use of corticosteroids may result in posterior subcapsular cataract formation. Patients should not wear contact lenses during their course of therapy with Loteprednol Etabonate Ophthalmic Ointment. Loteprednol Etabonate ophthalmic ointment 0.5% should not be used in children following ocular surgery. Its use may interfere with amblyopia treatment by hindering the child’s ability to see out of the operated eye. Adverse Effect: Adverse reactions associated with ophthalmic steroids include elevated intraocular pressure, which may be associated with optic nerve damage, visual acuity and field defects, posterior subcapsular cataract formation, secondary ocular infection from pathogens including herpes simplex, and perforation of the globe where there is thinning of the cornea or sclera. Information to Patients: Follow the instructions that are provided by your doctor and if the adverse effects persist, discontinue the usage and contact your doctor immediately. Presentation: EDNOL Ophthalmic Ointment is available in 5g pack of Laminated Plastic Tube.